AI-Powered Hepatitis C Single-Encounter Test-and-Treat
Key facts
- Where
- Lexington, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 22 and 65 years old?
Source: NCT07793643, who can take part
Where in United States
- University of KentuckyLexington, United StatesContact: Patrick GraceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Patrick Grace
- Trial code
- NCT07793643
- Record updated
- 28 August 2026
- Original description
This study will evaluate a single-visit approach to hepatitis C treatment in patients seen in the emergency department. Participants with hepatitis C will receive rapid testing and, if eligible, hepatitis C medication before leaving the emergency department. The study will also use a smart pillbox, an AI-powered virtual agent, and community health worker support to help participants take their medication as prescribed. Participants will have follow-up visits and testing to assess medication adherence and whether the hepatitis C infection is cured.Read full original descriptionShow less
This study will evaluate a single-visit approach to hepatitis C treatment in patients seen in the emergency department. Participants with hepatitis C will receive rapid testing and, if eligible, hepatitis C medication before leaving the emergency department. The study will also use a smart pillbox, an AI-powered virtual agent, and community health worker support to help participants take their medication as prescribed. Participants will have follow-up visits and testing to assess medication adherence and whether the hepatitis C infection is cured.
Inclusion: Age 22-65 years old, presenting to the Emergency Department (ED) who are undergoing antibody testing as part of universal screening; Patients to be discharged from the ED or ED Observational units.
Exclusion: Known prior liver biopsy showing cirrhosis; •Pregnancy; Followed by hospice or transplant, have a life expectancy < 1 year; Chronic Kidney Disease (CKD) or on dialysis; Allergy to study medications; Known clinical evidence of cirrhosis (egliver nodularity and/or splenomegaly on imaging, platelet count <150,000/m3, etc.); Capacity to Consent; Emergency Severity Index (ESI) Level one (high acuity patients); Known noninvasive serologic tests above proprietary cutoffs indicating cirrhosis (example - FibroSure, Enhanced Liver Fibrosis Test, etc.); Known or suspected Hepatocellular carcinoma; Patients admitted to the hospital.